Published 4 days ago • loading... • Updated 4 days ago

Phase 2 Published Data of Oveporexton Shows Broad Improvements of Narcolepsy Type 1 Symptoms

The investigational oral orexin receptor 2-selective agonist oveporexton is designed to restore orexin signaling to address the underlying orexin deficiency that is caused by narcolepsy type 1.

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

Sleep Education

Bridging Perspectives: Uniting the Narcolepsy Community for Change

The future of Narcolepsy needs us all. Join Wake Up Narcolepsy (WUN) for an insightful convening that will foster collaboration, share professional and lived experiences as well as discuss innovative ways to improve the lives of those affected by this condition.⁠ Bridging Perspectives leans into more than fifteen years of WUN’s relationship building amongst key constituents including people with Narcolepsy or Idiopathic Hypersomnia (IH), treatme…

4 days ago

Read Full Article

neurologylive.com

Phase 2 Published Data of Oveporexton Shows Broad Improvements of Narcolepsy Type 1 Symptoms

The investigational oral orexin receptor 2-selective agonist oveporexton is designed to restore orexin signaling to address the underlying orexin deficiency that is caused by narcolepsy type 1.

4 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right